Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and after the COVID-19 Era
mediaposted on 2022-05-06, 08:19 authored by Stefan Schreiber, Shomron Ben-Horin, Rieke Alten, Rene Westhovens, Laurent Peyrin-Biroulet, Silvio Danese, Toshifumi Hibi, Ken Takeuchi, Fernando Magro, Yoorim An, Dong-Hyeon Kim, SangWook Yoon, Walter Reinisch
Article full text
The above graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2022.